netFormulary Oxfordshire Clinical Commissioning Group NHS
Formulary  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
08.03.04.01  Expand sub section  Breast cancer
Anastrozole
View adult BNF View SPC online View childrens BNF
Formulary
Amber Continuation

Suitable for prescribing in primary care following

  • Oncology Consultant recommendation for adjuvant hormonal therapy of breast cancer as per NICE TA112In line with Endocrine Therapy in Breast Cancer Guidelines (APCO May 2007).
  • Genetics service recommendation for prevention of breast cancer in women at high and moderate risk of breast cancer as per NICE CG164 (APCO May 2018). 
 
Link  NICE CG164: Familial Breast Cancer
   
Exemestane
View adult BNF View SPC online View childrens BNF
Formulary

Amber Traffic Light  Suitable for prescribing in primary care following Oncology Consultant recommendation for adjuvant hormonal therapy of breast cancer as per NICE TA112. In line with Endocrine Therapy in Breast Cancer Guidelines.

APCO May 2007.

Red Traffic Light  In combination with everolimus for treating advanced breast cancer after endocrine therapy as per NICE TA421. In line with Endocrine Therapy in Breast Cancer Guidelines.

APCO January 2017.

 
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
   
Letrozole
View adult BNF View SPC online View childrens BNF
Formulary

Amber Traffic Light Suitable for prescribing in primary care following Oncology Consultant recommendation for adjuvant hormonal therapy of breast cancer as per NICE TA112.

APCO May 2007.

Red Traffic Light Second line ovulation induction treatment for patients that have unsuccessful clomiphene citrate ovulation induction or are intolerable to the side effects of clomiphene citrate.

APCO September 2018.


 
   
Raloxifene (Evirex®)
View adult BNF View SPC online View childrens BNF
Formulary
Amber Continuation

Suitable for prescribing in primary care following recommendation from genetics service for prevention of breast cancer in women at high and moderate risk of breast cancer as per NICE CG164.

APCO May 2018. 

 

 
Link  NICE CG164: Familial breast cancer
   
Tamoxifen
View adult BNF View SPC online View childrens BNF
Formulary

Amber Traffic Light  Suitable for prescribing in primary care following

  • Oncology Consultant recommendation for breast cancerIn line with Endocrine Therapy in Breast Cancer Guidelines (APCO July 2016).
  • Genetics service recommendation for the prevention of breast cancer in women at high and moderate risk of breast cancer as per NICE CG164 (APCO May 2018). 

Red Traffic Light  Tamoxifen 20mg is for secondary care use only for treating hereditary Haemorrhagic Telangectasia (HHT) (APCO July 2018).

 
Link  MHRA Drug Safety Update: Drug interactions, genetic variants and variability in clinical response
Link  NICE CG164: Familial Breast Cancer
Link  UKMI Q&A: Does Tamoxifen interact with SSRI or SNRI antidepressants?
   
 ....
 Non Formulary Items
Fulvestrant  (Faslodex®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black

For:

  • The treatment of locally advanced or metastatic breast cancer as per NICE TA239 (APCO January 2012).
  • For treating locally advanced or metastatic oestrogen-receptor positive breast cancer as per NICE TA503 (APCO March 2018).
Link  NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Link  NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
 
Toremifene  (Fareston®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Red: Medicines which should only be prescribed in secondary care by a specialist.  

Amber Continuation

Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.   

Amber Shared Care Protocol

Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).   

Green

Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.   

Brown

Brown: Medicines which should only be prescribed in restricted circumstances.  

Black

Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.  

OCCG Green

not used  

netFormulary